登录 注册 会员服务 联系我们

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

  • Published:2023-12 Issue:20 Volume:149 Page:18215-18240
  • ISSN:0171-5216
  • Container-title:Journal of Cancer Research and Clinical Oncology
  • language:en
  • Short-container-title:J Cancer Res Clin Oncol

Author:

Kang Dengxiong,Liu Siping,Yuan Xin,Liu Shenxiang,Zhang Zhengrong,He Zhilian,Yin Xudong,Mao Haiyan

Funder

Traditional Chinese Medicine Science and Technology Development Plan Project of Jiangsu

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Reference90 articles.

1. Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang N, Zandberg DP et al (2022) Dual checkpoint targeting of B7–H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-004424

2. Ali WAS, Huang X, Wu Y, Ma Y, Pan H, Liao J, Yang Z, Hong S, Yang Y, Huang Y et al (2023) Pretreatment serum lactate dehydrogenase and metastases numbers as potential determinants of anti-PD-1 therapy outcome in nasopharyngeal carcinoma. Cancer Control J Moffitt Cancer Cent 30:10732748221148912. https://doi.org/10.1177/10732748221148912

3. Arribas L, Plana M, Taberna M, Sospedra M, Vilariño N, Oliva M, Pallarés N, González Tampán AR, Del Rio LM, Mesia R et al (2021) Predictive value of skeletal muscle mass in recurrent/metastatic head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors. Front Oncol 11:699668. https://doi.org/10.3389/fonc.2021.699668

4. Baniyash M (2016) Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy. Cancer Immunol Immunother CII 65:857–867. https://doi.org/10.1007/s00262-016-1849-y

5. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A et al (2017) Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 35:1542–1549. https://doi.org/10.1200/JCO.2016.70.1524
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3